Q1 revenue came in at an all-time high of NOK 16.2m (up 15% from Q4/19). fCAL continues its strong growth trend, although Covid-19 might affect the Q2 numbers. Cystatin C is performing well as the kidney marker is also used in acute settings and is less affected by Covid-19. GCAL and fPELA should secure higher revenue growth in H2/20 + H1/21. The development of fCAL revenue and the clinical validation of GCAL are factors to follow closely in 2020.
27 Apr 2020
All-time high quarterly revenue
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
All-time high quarterly revenue
Q1 revenue came in at an all-time high of NOK 16.2m (up 15% from Q4/19). fCAL continues its strong growth trend, although Covid-19 might affect the Q2 numbers. Cystatin C is performing well as the kidney marker is also used in acute settings and is less affected by Covid-19. GCAL and fPELA should secure higher revenue growth in H2/20 + H1/21. The development of fCAL revenue and the clinical validation of GCAL are factors to follow closely in 2020.